Catalyst /
Jacobus
Catalyst Pharmaceuticals adds U.S. and Mexico rights to Ruzurgi
- Terms
- Not stated
- Stage
- Closed
What happened
Catalyst Pharmaceuticals, Inc. closed its purchase of assets and license rights from Jacobus Pharmaceutical Company, Inc. The transaction gives Catalyst rights to develop and commercialize Ruzurgi in the United States and Mexico.
Catalyst also purchased Jacobus’ U.S. patents, new drug applications and certain inventory for Ruzurgi.
The source
Everything on this page comes from the source below.
Catalyst Pharmaceuticals adds U.S. and Mexico rights to Ruzurgi
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly